Results 191 to 200 of about 1,121,449 (385)
The use of gene-fusions to determine membrane protein topology in Saccharomyces cerevisiae [PDF]
, 1989 Gregory Green +2 more
openalex +1 more source
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Molecular Oncology, Volume 19, Issue 5, Page 1404-1421, May 2025.We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock +10 more
wiley +1 more source
The fusion-related hydrophobic domain of Sendai F protein can be moved through the cytoplasmic membrane of Escherichia coli. [PDF]
, 1986 Nicholas G. Davis, Ming‐Chen Hsu
openalex +1 more source
Development of a novel fusion system for soluble protein overexpression and purification in Escherichia coli [PDF]
, 2010 Recombinant protein production is a useful technology for therapeutic and diagnostic applications. The bacterium Escherichia coli is widely used for the bioproduction of proteins, but still presents some drawbacks.
Castro, António +2 more
core
Molecular Oncology, Volume 19, Issue 5, Page 1452-1470, May 2025.Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti +8 more
wiley +1 more source
Synthesis of a (desSer1 Ile29 Leu89) chicken cystatin gene, expression in E. coli as fusion protein and its isolation [PDF]
, 1989 Ennes A. Auerswald +4 more
openalex +1 more source
Molecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana +17 more
wiley +1 more source